A phase I/II study of prexasertib in combination with irinotecan in patients with relapsed/refractory desmoplastic small round cell tumor and rhabdomyosarcoma.
Emily K. Slotkin(Memorial Sloan Kettering Cancer Center), William D. Tap(Memorial Sloan Kettering Cancer Center), Viswatej Avutu(Memorial Sloan Kettering Cancer Center), Paul A. Meyers(Memorial Sloan Kettering Cancer Center), Scarlett Rodriguez(Memorial Sloan Kettering Cancer Center), Audrey Mauguen(Memorial Sloan Kettering Cancer Center), Katherine A. Thornton(Memorial Sloan Kettering Cancer Center), Mrinal M. Gounder(Memorial Sloan Kettering Cancer Center), Tara J. O’Donohue, Mark A. Dickson(Memorial Sloan Kettering Cancer Center), Benjamin A. Nacev(University of Pittsburgh), Evan Rosenbaum(Memorial Sloan Kettering Cancer Center), Filemon S. Dela Cruz, Mary Louise Keohan(Roche (Switzerland)), Ciara M. Kelly(Memorial Sloan Kettering Cancer Center), Leonard H. Wexler(Memorial Sloan Kettering Cancer Center), Michael V. Ortiz(Memorial Sloan Kettering Cancer Center), Julia Glade Bender(Columbia University Irving Medical Center), Sandra P. D’Angelo(Memorial Sloan Kettering Cancer Center), Michael D. Kinnaman(Regeneron (United States))
Cited by 14
Related Papers
Tumour exosome integrins determine organotropic metastasis
|Nature|2015|5.2k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
|Journal of Clinical Oncology|2015|1.1k
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|733